Base de dados : MEDLINE
Pesquisa : D02.455.526.728.650.156.700 [Categoria DeCS]
Referências encontradas : 142 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 15 ir para página                         

  1 / 142 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26522808
[Au] Autor:Park S; Hong J; Hwang I; Ahn JY; Cho EY; Park J; Cho EK; Shin DB; Lee JH
[Ad] Endereço:Department of Medicine, Gachon University School of Medicine, Incheon 405-760, Republic of Korea.
[Ti] Título:Comprehensive geriatric assessment in elderly patients with newly diagnosed aggressive non-Hodgkin lymphoma treated with multi-agent chemotherapy.
[So] Source:J Geriatr Oncol;6(6):470-8, 2015 Nov.
[Is] ISSN:1879-4076
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: The purpose of this prospective observational study is to evaluate the relation of the comprehensive geriatric assessment (CGA) to tolerability and survival of multi-agent chemotherapy for curative intent in elderly patients with aggressive non-Hodgkin lymphoma (NHL). MATERIALS AND METHODS: Patients who were 1) age ≥65 years, 2) newly diagnosed aggressive NHL, and 3) treated with multi-agent chemotherapy within 2 weeks from the time of diagnosis were enrolled from January 2011 to June 2014. Baseline clinical, laboratory, and CGA data being composed of Mini Nutritional Assessment-Short Form (MNA-SF), Korean version of Mini Mental Status Exam, Korean-Geriatric Depression Scale, and Groningen Frailty Index (GFI), were collected and analyzed for the relation to the outcome factors. RESULTS: Seventy patients were included; the median age was 73.5 years, 27 (38.6%) patients were Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 2 or more, and half of the patients were high or high-intermediate risk by age-adjusted international prognostic index (aaIPI). Most patients received CHOP or CHOP-like chemotherapy. Factors affecting discontinuation of chemotherapy within 12 weeks were poor MNA-SF, poor GFI, poor PS, and presence of B symptom. Among those, poor MNA-SF was independent of other variables in multivariate analysis. Poor MNA-SF, bone marrow involvement, and baseline anemia of hemoglobin<10g /dL were found to be independent factors associated with inferior overall survival whereas aaIPI factors were not. CONCLUSION: MNA-SF predicted tolerability to multi-agents chemotherapy and overall survival in elderly patients with aggressive NHL who were treated with multi-agent chemotherapy.
[Mh] Termos MeSH primário: Avaliação Geriátrica
Linfoma não Hodgkin/epidemiologia
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Ciclofosfamida/uso terapêutico
Doxorrubicina/uso terapêutico
Etoposídeo/uso terapêutico
Feminino
Idoso Fragilizado
Glioxal/uso terapêutico
Seres Humanos
Ifosfamida/uso terapêutico
Linfoma não Hodgkin/tratamento farmacológico
Linfoma não Hodgkin/patologia
Masculino
Análise Multivariada
Gradação de Tumores
Prednimustina/uso terapêutico
Prednisona/uso terapêutico
Estudos Prospectivos
República da Coreia/epidemiologia
Resultado do Tratamento
Vincristina/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
50NP6JJ975 (Glyoxal); 5J49Q6B70F (Vincristine); 6PLQ3CP4P3 (Etoposide); 80168379AG (Doxorubicin); 8N3DW7272P (Cyclophosphamide); 9403SIO2S8 (Prednimustine); UM20QQM95Y (Ifosfamide); VB0R961HZT (Prednisone)
[Em] Mês de entrada:1609
[Cu] Atualização por classe:151125
[Lr] Data última revisão:
151125
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151103
[St] Status:MEDLINE


  2 / 142 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:20720088
[Au] Autor:Scholz M; Engert A; Franklin J; Josting A; Diehl V; Hasenclever D; Loeffler M; German Hodgkin's Lymphoma Study Group
[Ad] Endereço:Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany. markus.scholz@imise.uni-leipzig.de
[Ti] Título:Impact of first- and second-line treatment for Hodgkin's lymphoma on the incidence of AML/MDS and NHL--experience of the German Hodgkin's Lymphoma Study Group analyzed by a parametric model of carcinogenesis.
[So] Source:Ann Oncol;22(3):681-8, 2011 Mar.
[Is] ISSN:1569-8041
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Using a parametric carcinogenesis model, we disentangle the superimposing effects of primary and relapse therapies of Hodgkin's disease on secondary neoplasias. PATIENTS AND METHODS: We analyze eight randomized trials of the German Hodgkin's lymphoma study group [5357 individuals, 67 secondary acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS) and 97 secondary non-Hodgkin's lymphoma (NHL)]. Primary therapies were divided into four groups: radiotherapy alone, moderately dosed COPP/ABVD-like chemotherapies for intermediate and advanced stages and BEACOPP escalated. RESULTS: For secondary AML/MDS, the hazards after primary therapies are proportional (maximum at 3.4 years), while the hazard after relapse therapy is more peaked (maximum at 1.8 years). Intermediate and advanced stage chemotherapy resulted in a cumulative risk of 1.5%, while the risk after BEACOPP escalated is higher (4.4%, P = 0.004) and comparable with that after relapse therapy (4.5%). For secondary NHL, there are no differences in cumulative risk between the primary therapies (2.9%), while the risk after relapse therapy is increased (6.6%, P = 0.002). CONCLUSIONS: BEACOPP escalated moderately increases the risk of secondary AML/MDS but not NHL. No differences were found between other chemotherapies of advanced stages and intermediate stages. Secondary AML/MDS occurs faster after relapse treatment than after primary treatment.
[Mh] Termos MeSH primário: Doença de Hodgkin/tratamento farmacológico
Leucemia Mieloide Aguda/induzido quimicamente
Linfoma não Hodgkin/induzido quimicamente
Síndromes Mielodisplásicas/induzido quimicamente
Segunda Neoplasia Primária/induzido quimicamente
[Mh] Termos MeSH secundário: Algoritmos
Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos
Bleomicina/efeitos adversos
Ciclofosfamida/efeitos adversos
Dacarbazina/efeitos adversos
Doxorrubicina/efeitos adversos
Etoposídeo/efeitos adversos
Glioxal/efeitos adversos
Doença de Hodgkin/mortalidade
Doença de Hodgkin/radioterapia
Seres Humanos
Ifosfamida/efeitos adversos
Estimativa de Kaplan-Meier
Leucemia Mieloide Aguda/mortalidade
Leucemia Mieloide Aguda/prevenção & controle
Linfoma não Hodgkin/mortalidade
Linfoma não Hodgkin/prevenção & controle
Síndromes Mielodisplásicas/mortalidade
Síndromes Mielodisplásicas/prevenção & controle
Segunda Neoplasia Primária/mortalidade
Segunda Neoplasia Primária/prevenção & controle
Prednimustina/efeitos adversos
Prednisona/efeitos adversos
Procarbazina/efeitos adversos
Modelos de Riscos Proporcionais
Ensaios Clínicos Controlados Aleatórios como Assunto
Medição de Risco
Resultado do Tratamento
Vimblastina/efeitos adversos
Vincristina/efeitos adversos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
11056-06-7 (Bleomycin); 35S93Y190K (Procarbazine); 50NP6JJ975 (Glyoxal); 5J49Q6B70F (Vincristine); 5V9KLZ54CY (Vinblastine); 6PLQ3CP4P3 (Etoposide); 7GR28W0FJI (Dacarbazine); 80168379AG (Doxorubicin); 8N3DW7272P (Cyclophosphamide); 9403SIO2S8 (Prednimustine); UM20QQM95Y (Ifosfamide); VB0R961HZT (Prednisone)
[Em] Mês de entrada:1106
[Cu] Atualização por classe:161017
[Lr] Data última revisão:
161017
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:100820
[St] Status:MEDLINE
[do] DOI:10.1093/annonc/mdq408


  3 / 142 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:18800601
[Au] Autor:Yamaguchi M
[Ti] Título:[Treatment of localized nasal NK/T-cell lymphoma].
[So] Source:Rinsho Ketsueki;49(8):553-8, 2008 Aug.
[Is] ISSN:0485-1439
[Cp] País de publicação:Japan
[La] Idioma:jpn
[Mh] Termos MeSH primário: Linfoma Extranodal de Células T-NK/terapia
[Mh] Termos MeSH secundário: Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Carboplatina/administração & dosagem
Ensaios Clínicos como Assunto
Terapia Combinada
Ciclofosfamida/administração & dosagem
Dexametasona/administração & dosagem
Doxorrubicina/administração & dosagem
Etoposídeo/administração & dosagem
Glioxal/administração & dosagem
Seres Humanos
Ifosfamida/administração & dosagem
Transplante de Células-Tronco de Sangue Periférico
Prednimustina/administração & dosagem
Prednisolona/administração & dosagem
Prognóstico
Radioterapia/métodos
Vincristina/administração & dosagem
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
50NP6JJ975 (Glyoxal); 5J49Q6B70F (Vincristine); 6PLQ3CP4P3 (Etoposide); 7S5I7G3JQL (Dexamethasone); 80168379AG (Doxorubicin); 8N3DW7272P (Cyclophosphamide); 9403SIO2S8 (Prednimustine); 9PHQ9Y1OLM (Prednisolone); BG3F62OND5 (Carboplatin); UM20QQM95Y (Ifosfamide)
[Em] Mês de entrada:0810
[Cu] Atualização por classe:151119
[Lr] Data última revisão:
151119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:080920
[St] Status:MEDLINE


  4 / 142 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:16246422
[Au] Autor:Cho JH; Kim HS; Ko YH; Park CS
[Ad] Endereço:Department of Otolaryngology, Head and Neck Surgery, Kounkuk University Medical School, Seoul, South Korea.
[Ti] Título:Epstein-Barr virus infected natural killer cell lymphoma in a patient with hypersensitivity to mosquito bite.
[So] Source:J Infect;52(6):e173-6, 2006 Jun.
[Is] ISSN:1532-2742
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Hypersensitivity to mosquito bite (HMB) can occur in association with chronic Epstein-Barr virus (EBV) infection and natural killer (NK) cell leukaemia/lymphoma, which was named 'Tokura-Ishihara disease'. This disease is very rare and most previous reports have been documented in Japan. We present a patient who suffered from of pustules on skin, high fever, myalgia and multiple lymph node enlargements after mosquito bite from childhood. Recently, multiple lymph nodes were palpable on his both inguinal area. Peripheral blood smear (PBS) revealed many large granular lymphocytes and the skin lesion showed a dense dermal and subcutaneous infiltrate of lymphocytes. The lymph nodes and perinodal adipose tissue were infiltrated by atypical lymphoid cells in which EBER-positive signals were identified by in situ hybridization using EBV encoded RNA-1 probe. He was diagnosed as having Tokura-Ishihara disease and receives chemotherapy now. Here, we report a case of this disease with a precise pathological description on the lymph node biopsy.
[Mh] Termos MeSH primário: Infecções por Vírus Epstein-Barr/complicações
Hipersensibilidade/complicações
Mordeduras e Picadas de Insetos/imunologia
Células Matadoras Naturais/patologia
Linfoma/etiologia
[Mh] Termos MeSH secundário: Adulto
Animais
Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem
Biópsia
Culicidae
Infecções por Vírus Epstein-Barr/patologia
Etoposídeo/administração & dosagem
Glioxal/administração & dosagem
Seres Humanos
Ifosfamida/administração & dosagem
Mordeduras e Picadas de Insetos/patologia
Células Matadoras Naturais/virologia
Linfonodos/patologia
Linfócitos/patologia
Linfoma/tratamento farmacológico
Linfoma/patologia
Linfoma/virologia
Masculino
Prednimustina/administração & dosagem
Pele/patologia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
50NP6JJ975 (Glyoxal); 6PLQ3CP4P3 (Etoposide); 9403SIO2S8 (Prednimustine); UM20QQM95Y (Ifosfamide)
[Em] Mês de entrada:0801
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:051026
[St] Status:MEDLINE


  5 / 142 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:15064867
[Au] Autor:Brosteanu O; Hasenclever D; Loeffler M; Diehl V; German Hodgkin's Lymphoma Study Group
[Ad] Endereço:Coordinating Center for Clinical Trials, University of Leipzig, Prager Str. 34, 04317, Leipzig, Germany. oana.brosteanu@kksl.uni-leipzig.de
[Ti] Título:Low acute hematological toxicity during chemotherapy predicts reduced disease control in advanced Hodgkin's disease.
[So] Source:Ann Hematol;83(3):176-82, 2004 Mar.
[Is] ISSN:0939-5555
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:Chemotherapy-treated patients with advanced Hodgkin's disease (HD) differ considerably in acute hematotoxicity. Hematotoxicity may be indicative of pharmacological and metabolic heterogeneity. We hypothesized that low hematotoxicity might correlate with reduced systemic dose and thus reduced disease control. A total of 266 patients with advanced HD treated with cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, vinblastine, and dacarbazine (COPP-ABVD) were analyzed (HD6 trial of the German Hodgkin's Lymphoma Study Group). The reported WHO grade of leukocytopenia was averaged over chemotherapy cycles given and weighted with the reciprocal dose intensity of the corresponding cycle. The low and high toxicity groups were defined in retrospect as having had an averaged WHO grade of leukocytopenia 2.1, respectively. The independent impact of low hematological toxicity on freedom from treatment failure (FFTF) was assessed multivariately adjusting for the international prognostic score for advanced HD. The results were validated in two independent cohorts [181 patients treated with COPP-ABVD (HD9-trial) and 250 patients treated with COPP-ABV-ifosfamide, methotrexate, etoposide, and prednisone (IMEP) (HD6 trial)]. The 5-year FFTF rates were 68% for patients with high toxicity vs 47% for patients with low toxicity [multivariate relative risk (RR) 2.0, 95% confidence interval (CI) 1.4-3.0, p=0.0002]. Patients with low toxicity received significantly higher nominal dose ( p=0.02) and dose intensity ( p<0.0001). This finding was confirmed in both validation cohorts (multivariate RR 2.1, 95% CI 1.2-3.8, p=0.01 and RR 1.5, 95% CI 1.01-2.26, p=0.04, respectively). Patients with low hematotoxicity have significantly higher failure rates despite higher doses and dose intensity. Hematotoxicity is an independent prognostic factor for treatment outcome. This observation suggests a strategy of individualized dosing adapted to hematotoxicity.
[Mh] Termos MeSH primário: Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem
Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos
Medula Óssea/efeitos dos fármacos
Doenças Hematológicas/induzido quimicamente
Doença de Hodgkin/tratamento farmacológico
[Mh] Termos MeSH secundário: Bleomicina/administração & dosagem
Bleomicina/efeitos adversos
Estudos de Coortes
Ciclofosfamida/administração & dosagem
Ciclofosfamida/efeitos adversos
Dacarbazina/administração & dosagem
Dacarbazina/efeitos adversos
Doxorrubicina/administração & dosagem
Doxorrubicina/efeitos adversos
Etoposídeo/administração & dosagem
Etoposídeo/efeitos adversos
Feminino
Glioxal/administração & dosagem
Glioxal/efeitos adversos
Doença de Hodgkin/patologia
Seres Humanos
Ifosfamida/administração & dosagem
Ifosfamida/efeitos adversos
Masculino
Prednimustina/administração & dosagem
Prednimustina/efeitos adversos
Prednisona/administração & dosagem
Prednisona/efeitos adversos
Procarbazina/administração & dosagem
Procarbazina/efeitos adversos
Prognóstico
Estudos Retrospectivos
Índice de Gravidade de Doença
Resultado do Tratamento
Vimblastina/administração & dosagem
Vimblastina/efeitos adversos
Vincristina/administração & dosagem
Vincristina/efeitos adversos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
11056-06-7 (Bleomycin); 35S93Y190K (Procarbazine); 50NP6JJ975 (Glyoxal); 5J49Q6B70F (Vincristine); 5V9KLZ54CY (Vinblastine); 6PLQ3CP4P3 (Etoposide); 7GR28W0FJI (Dacarbazine); 80168379AG (Doxorubicin); 8N3DW7272P (Cyclophosphamide); 9403SIO2S8 (Prednimustine); UM20QQM95Y (Ifosfamide); VB0R961HZT (Prednisone)
[Em] Mês de entrada:0404
[Cu] Atualização por classe:151119
[Lr] Data última revisão:
151119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:040406
[St] Status:MEDLINE


  6 / 142 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:14760122
[Au] Autor:Sieber M; Tesch H; Pfistner B; Rueffer U; Paulus U; Munker R; Hermann R; Doelken G; Koch P; Oertel J; Roller S; Worst P; Bischof H; Glunz A; Greil R; von Kalle K; Schalk KP; Hasenclever D; Brosteanu O; Duehmke E; Georgii A; Engert A; Loeffler M; Diehl V; Mueller RP; Willich N; Fischer R; Hansmann ML; Stein H; Schober T; Koch B; German Hodgkin's Lymphoma Study Group
[Ad] Endereço:Klinik I für Innere Medizin, University of Cologne, Cologne, Germany. sieer@kkh-gummersbach.de
[Ti] Título:Treatment of advanced Hodgkin's disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: final results of the German Hodgkin's Lymphoma Study Group HD6 trial.
[So] Source:Ann Oncol;15(2):276-82, 2004 Feb.
[Is] ISSN:0923-7534
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The purpose of this study was to compare the efficacy of the hybrid chemotherapeutic regimen COPP/ABV/IMEP (cyclophosphamide-vincristine-procarbazine-prednisone-doxorubicin-bleomycin-vinblastine-ifosfamide-methotrexate-etoposide) (CAI) with that of the standard regimen COPP/ABVD (COPP/ABV, dacarbacine) (CA) in the treatment of advanced-stage Hodgkin's disease (HD). PATIENTS AND METHODS: Between January 1988 and January 1993, 588 eligible patients with HD in stages IIIB and IV were randomly assigned to a treatment or control group. The treatment group received four cycles of CAI over a complete cycle duration of 43 days. The control group received four cycles of CA over 57 days. Both groups then received consolidating radiotherapy. RESULTS: Five hundred and eighty-four patients were suitable for arm comparison. Patients in each group were similar in age, sex, histological subtype and clinical risk factors. Complete remission rates, overall survival and freedom from treatment failure at 7 years were similar for the two groups: 77% versus 78%, 73% versus 73% and 54% versus 56% for CAI and CA, respectively. Differences in acute chemotherapy-related toxicity were significant, however. Prognostic factor analysis confirmed the relevance of the International Prognostic Index and revealed that stage IVB, low hemoglobin, low lymphocyte count, high age and male gender were associated with a poor prognosis CONCLUSION: The rapidly alternating hybrid CAI did not give superior results when compared with the standard regimen CA in advanced-stage HD.
[Mh] Termos MeSH primário: Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Doença de Hodgkin/tratamento farmacológico
Doença de Hodgkin/radioterapia
[Mh] Termos MeSH secundário: Adolescente
Adulto
Fatores Etários
Idoso
Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem
Bleomicina/administração & dosagem
Terapia Combinada
Ciclofosfamida/administração & dosagem
Dacarbazina/administração & dosagem
Doxorrubicina/administração & dosagem
Esquema de Medicação
Etoposídeo/administração & dosagem
Feminino
Glioxal/administração & dosagem
Doença de Hodgkin/patologia
Seres Humanos
Ifosfamida/administração & dosagem
Masculino
Meia-Idade
Prednimustina/administração & dosagem
Prednisona/administração & dosagem
Procarbazina/administração & dosagem
Prognóstico
Fatores Sexuais
Resultado do Tratamento
Vimblastina/administração & dosagem
Vincristina/administração & dosagem
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
11056-06-7 (Bleomycin); 35S93Y190K (Procarbazine); 50NP6JJ975 (Glyoxal); 5J49Q6B70F (Vincristine); 5V9KLZ54CY (Vinblastine); 6PLQ3CP4P3 (Etoposide); 7GR28W0FJI (Dacarbazine); 80168379AG (Doxorubicin); 8N3DW7272P (Cyclophosphamide); 9403SIO2S8 (Prednimustine); UM20QQM95Y (Ifosfamide); VB0R961HZT (Prednisone)
[Em] Mês de entrada:0406
[Cu] Atualização por classe:161017
[Lr] Data última revisão:
161017
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:040205
[St] Status:MEDLINE


  7 / 142 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:11882971
[Au] Autor:Oborotova NA; Smirnova ZS; Polozkova ZS; Baryshnikov AIu
[Ti] Título:[Pharmacological aspects in the development of liposomal medicinal preparations for the internal injection of hydrophobic cytostatics].
[Ti] Título:Farmatsevticheskie aspekty razrabotki liposomal'nykh lekarstvennykh form dlia vnutrivennogo vvedeniia hidrofobnykh tsitostatikov..
[So] Source:Vestn Ross Akad Med Nauk;(1):42-5, 2002.
[Is] ISSN:0869-6047
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:To improve the action and selectivity of new drugs on tumor cells and the use of currently available pharmaceutical technologies to develop the systems of controlled transport of well-known antitumor compounds is one of the ways of enhancing the efficiency of drug therapy for tumors. The tropicity of steroid hormones to definite organs and tissues makes it possible to use them as specific messengers of alkylating groups to target tissues and tumors. Hormone cytostatics synthesized by this principle have a double mechanism of hormonal and cytotoxic actions. The original Russian water-insoluble hormone cytostatistics testifenon, kortifen, and cytestrol acetate demonstrated local tissue irritation together with high antitumor activity. No rational dosage forms make it possible to conduct clinical trials by parenteral administration. The aim of this paper is to summarize the authors' results of designing hydrophobic antitumor hormone cytostatics. The advantages and disadvantages of different approaches to designing traditional dosage forms and to applying colloid liposomal systems for intravenous administration of water-insoluble agents are shown.
[Mh] Termos MeSH primário: Antineoplásicos Alquilantes/administração & dosagem
Antineoplásicos Alquilantes/farmacologia
Antineoplásicos Hormonais/administração & dosagem
Antineoplásicos Hormonais/farmacologia
Corticosterona/análogos & derivados
Corticosterona/administração & dosagem
Corticosterona/farmacologia
Lipossomos/metabolismo
Compostos de Mostarda Nitrogenada/administração & dosagem
Compostos de Mostarda Nitrogenada/farmacologia
Prednimustina/administração & dosagem
Prednimustina/farmacologia
[Mh] Termos MeSH secundário: Biomarcadores Tumorais
Feminino
Seres Humanos
Injeções Intravenosas
[Pt] Tipo de publicação:ENGLISH ABSTRACT; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antineoplastic Agents, Alkylating); 0 (Antineoplastic Agents, Hormonal); 0 (Biomarkers, Tumor); 0 (Liposomes); 0 (Nitrogen Mustard Compounds); 0 (cortifen); 9403SIO2S8 (Prednimustine); W980KJ009P (Corticosterone)
[Em] Mês de entrada:0207
[Cu] Atualização por classe:161020
[Lr] Data última revisão:
161020
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:020309
[St] Status:MEDLINE


  8 / 142 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:11848547
[Au] Autor:Peters-Engl C; Medl M; Denison U; Sevelda P; Leodolter S; Petru E
[Ad] Endereço:Department of Gynecology and Obstetrics, Lainz Medical Center, Vienna, Austria.
[Ti] Título:Does long-term application of granulocyte colony-stimulating factor adversely influence overall survival in patients with ovarian cancer? A clinical study.
[So] Source:Anticancer Res;21(5):3701-6, 2001 Sep-Oct.
[Is] ISSN:0250-7005
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:The purpose of this study was to investigate the effect of long-term administration of G-CSF with regard to its impact on overall survival of patients with ovarian cancer. We report the results of a non-randomized trial on 64 patients with advanced ovarian cancer treated with 6 cycles of conventional chemotherapy. Chemotherapy comprised carboplatin 400 mg/m2 and epirubicin 70 mg/m2 on day 1 of each cycle and prednimustine 100 mg/m2 on days 3 to 7, every 28 days. Thirty-three patients received CEP chemotherapy with G-CSF support whereas 31 women received CEP chemotherapy alone. The schedule of G-CSF was 5 mg/kg/day subcutanously on days 8 to 21 of each cycle. The severity of reduction in white cells and neutrophil count was significantly different in the two treatment groups (p<0.05), with more toxicity in the non- G-CSF group. G-CSF users had a non significant 0.88-fold lower risk of dying from ovarian cancer (95% CI, 0.48-1.60, p=0.678). In a survival analysis using a Cox proportional hazards model, residual tumor remained as an independent prognostic factor. The increasing amount of residual tumor resulted in a 1.767-fold higher risk (95% CI, 1.23-2.53, p=0.002) of death secondary to the underlying disease. In conclusion, this trial has failed to demonstrate any negative impact on patients' overall survival for the additional use of G-CSF with platinum-based chemotherapy; our results were consistent with the beneficial effects of G-CSF treatment on cytotoxic chemotherapy-induced myelosuppression.
[Mh] Termos MeSH primário: Fator Estimulador de Colônias de Granulócitos/efeitos adversos
Neoplasias Ovarianas/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Idoso
Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Carboplatina/administração & dosagem
Carboplatina/efeitos adversos
Esquema de Medicação
Epirubicina/administração & dosagem
Epirubicina/efeitos adversos
Feminino
Fator Estimulador de Colônias de Granulócitos/administração & dosagem
Seres Humanos
Meia-Idade
Prednimustina/administração & dosagem
Prednimustina/efeitos adversos
Taxa de Sobrevida
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE
[Nm] Nome de substância:
143011-72-7 (Granulocyte Colony-Stimulating Factor); 3Z8479ZZ5X (Epirubicin); 9403SIO2S8 (Prednimustine); BG3F62OND5 (Carboplatin)
[Em] Mês de entrada:0203
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:020219
[St] Status:MEDLINE


  9 / 142 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:11168502
[Au] Autor:Rodon P; Linassier C; Gauvain JB; Benboubker L; Goupille P; Maigre M; Luthier F; Dugay J; Lucas V; Colombat P
[Ad] Endereço:Department of Internal Medicine and Haematology, Centre Hospitalier Général, Blois, France. rodon.philippe@wanadoo.fr
[Ti] Título:Multiple myeloma in elderly patients: presenting features and outcome.
[So] Source:Eur J Haematol;66(1):11-7, 2001 Jan.
[Is] ISSN:0902-4441
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Few studies have been performed regarding multiple myeloma (MM) in elderly patients. We report a retrospective series of 130 unselected patients with MM aged 75 yr or more at diagnosis. Presenting features were identical to those reported in younger patients, except for a higher rate of infection. Heavy comorbidity was characteristic of unselected geriatric patients. Ninety-four patients received conventional chemotherapy. The response rate was 62%. Treatment toxicity was mild. Median survival was 22 months. Durie-Salmon (DS) clinical stages II and III MM were severe and often led to death, while significantly more patients with DS stage I MM died from unrelated causes (p<0.0001). Univariate analysis showed that age > or = 85 yr, performance status > or = 2, creatinine level > or = 120 micromol/l, beta 2 microglobulin level > 4 mg/l, C-reactive protein level > 6 mg/l, platelet count < 100 x 10(9)/l, presence of infection and lack of response to chemotherapy were adverse prognostic factors for survival. In Cox multivariate regression analysis, age > or = 85 yr (p<0.0001), performance status > or = 2 (p<0.0001) and creatinine level > or = 120 micromol/l (p<0.0001) were independent factors in predicting short survival. This study provides evidence that in patients with symptomatic MM age should not be considered as a major obstacle to active treatment. Prospective clinical trials are needed in this population of patients and should include an assessment of quality of life.
[Mh] Termos MeSH primário: Mieloma Múltiplo/epidemiologia
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Causas de Morte
Comorbidade
Ciclofosfamida/administração & dosagem
Dexametasona/administração & dosagem
Doxorrubicina/administração & dosagem
Etoposídeo/administração & dosagem
Feminino
França/epidemiologia
Seres Humanos
Interferon-alfa/administração & dosagem
Tábuas de Vida
Lomustina/administração & dosagem
Masculino
Melfalan/administração & dosagem
Mieloma Múltiplo/sangue
Mieloma Múltiplo/diagnóstico
Mieloma Múltiplo/tratamento farmacológico
Mieloma Múltiplo/patologia
Proteínas do Mieloma/análise
Estadiamento de Neoplasias
Síndromes Paraneoplásicas/epidemiologia
Prednimustina/administração & dosagem
Prednisona/administração & dosagem
Prognóstico
Modelos de Riscos Proporcionais
Estudos Retrospectivos
Análise de Sobrevida
Resultado do Tratamento
Vincristina/administração & dosagem
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY; REVIEW
[Nm] Nome de substância:
0 (Interferon-alpha); 0 (Myeloma Proteins); 5J49Q6B70F (Vincristine); 6PLQ3CP4P3 (Etoposide); 7BRF0Z81KG (Lomustine); 7S5I7G3JQL (Dexamethasone); 80168379AG (Doxorubicin); 8N3DW7272P (Cyclophosphamide); 9403SIO2S8 (Prednimustine); Q41OR9510P (Melphalan); VB0R961HZT (Prednisone)
[Em] Mês de entrada:0102
[Cu] Atualização por classe:151119
[Lr] Data última revisão:
151119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:010213
[St] Status:MEDLINE


  10 / 142 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:10999723
[Au] Autor:Filipits M; Jaeger U; Simonitsch I; Chizzali-Bonfadin C; Heinzl H; Pirker R
[Ad] Endereço:Division of Oncology, Department of Internal Medicine I, University of Vienna, Austria.
[Ti] Título:Clinical relevance of the lung resistance protein in diffuse large B-cell lymphomas.
[So] Source:Clin Cancer Res;6(9):3417-23, 2000 Sep.
[Is] ISSN:1078-0432
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Drug resistance of non-Hodgkin's lymphomas may involve mechanisms of the multidrug resistance phenotype including the lung resistance protein (LRP) and the multidrug resistance protein (MRP1). To determine the clinical relevance of these multidrug resistance factors in previously untreated diffuse large B-cell lymphomas (n = 48), we studied LRP and MRP1 expression in lymphoma cells and their impact on clinical outcome. LRP and MRP1 expression were immunohistochemically assessed by means of the monoclonal antibodies LRP-56 and MRPr1, respectively. LRP was positive in 23% and MRP1 in 44% of the samples. LRP expression was associated with higher tumor stage (P = 0.03), elevated serum lactate dehydrogenase levels (P = 0.01), and the International Prognostic Index (P = 0.0001). LRP-positive patients had a lower complete response rate to polychemotherapy than LRP-negative patients (18 versus 65%; P = 0.006). Patients with LRP expression had a shorter overall survival than those without LRP expression (median of 0.9 years versus median not reached; P = 0.001). MRP1 expression was independent of clinical and laboratory parameters and had no impact on the outcome of chemotherapy or survival of the patients. These data suggest that LRP expression but not MRP1 expression is an important mechanism of drug resistance associated with worse clinical outcome in previously untreated diffuse large B-cell lymphomas. Thus, the reversal of LRP-mediated drug resistance may improve clinical outcome in diffuse large B-cell lymphoma in the future.
[Mh] Termos MeSH primário: Transportadores de Cassetes de Ligação de ATP/biossíntese
Linfoma de Células B/tratamento farmacológico
Linfoma de Células B/metabolismo
Linfoma Difuso de Grandes Células B/tratamento farmacológico
Linfoma Difuso de Grandes Células B/metabolismo
Proteínas de Neoplasias/biossíntese
Partículas de Ribonucleoproteínas em Forma de Abóbada/biossíntese
[Mh] Termos MeSH secundário: Análise de Variância
Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Bleomicina/administração & dosagem
Ciclofosfamida/administração & dosagem
Citarabina/administração & dosagem
Doxorrubicina/administração & dosagem
Resistência a Múltiplos Medicamentos
Etoposídeo/administração & dosagem
Feminino
Seres Humanos
Imuno-Histoquímica
Lomustina/administração & dosagem
Masculino
Metotrexato/administração & dosagem
Meia-Idade
Proteínas Associadas à Resistência a Múltiplos Medicamentos
Prednimustina/administração & dosagem
Prednisona/administração & dosagem
Análise de Regressão
Análise de Sobrevida
Resultado do Tratamento
Vincristina/administração & dosagem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Multidrug Resistance-Associated Proteins); 0 (Neoplasm Proteins); 0 (Vault Ribonucleoprotein Particles); 0 (major vault protein); 04079A1RDZ (Cytarabine); 11056-06-7 (Bleomycin); 5J49Q6B70F (Vincristine); 6PLQ3CP4P3 (Etoposide); 7BRF0Z81KG (Lomustine); 80168379AG (Doxorubicin); 8N3DW7272P (Cyclophosphamide); 9403SIO2S8 (Prednimustine); VB0R961HZT (Prednisone); YL5FZ2Y5U1 (Methotrexate)
[Em] Mês de entrada:0102
[Cu] Atualização por classe:151119
[Lr] Data última revisão:
151119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:000922
[St] Status:MEDLINE



página 1 de 15 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde